---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-066954"
form_type: "8-K"
ticker: "MAIA"
cik: "0001878313"
company_name: "MAIA Biotechnology, Inc."
filed_at: "2024-03-13T23:59:59+00:00"
generated_at: "2026-06-04T22:33:19.960929+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# MAIA Biotechnology raises ~$2.92M in private placement of common stock and warrants

## Summary
- Sold 2,043,587 shares and warrants to accredited investors at $1.17/share for ~$2.4M gross.
- Directors purchased 452,731 shares and warrants at same price, raising ~$530,000.
- Warrants exercisable at $1.30 per share, beginning 6 months after issuance, 5-year term.
- Net proceeds to fund first third of pivotal THIO-101 trial Part C in NSCLC.
- Closing expected March 14, 2024; securities are restricted, no registration rights.

## SEC filing metadata
- accession: 0001193125-24-066954
- form_type: 8-K
- ticker: MAIA
- cik: 0001878313
- company_name: MAIA Biotechnology, Inc.
- filed_at: 2024-03-13T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1878313/000119312524066954/0001193125-24-066954-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1878313/000119312524066954/d778616d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-066954
- JSON: https://secwatch.observer/filing/0001193125-24-066954.json
- Plain text: https://secwatch.observer/filing/0001193125-24-066954.txt

## Key facts
- Material Agreements
  MAIA Biotechnology, Inc. entered into Securities Purchase Agreement with certain accredited investors valued at approximately $2.4 million (effective 2024-03-11).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain accredited investors
  - Value: approximately $2.4 million
  - Effective: 2024-03-11
  source text: On March 11, 2024, MAIA Biotechnology, Inc. (the " Company ") entered into a Securities Purchase Agreement (the " Purchase Agreement ") with certain accredited investors (the " Investors ") for the issuance and sale in a private placement (the " Private Placement ") of (i) 2,043,587 shares (the "Investor Shares") of the Company’s common stock, par value $0.0001 per share (" Common Stock "), and (ii) warrants (the " Investor Warrants ") to purchase up to 2,043,587 shares of the Company’s Common Stock, at a price per share of $1.17 for an aggregate purchase price of approximately $2.4 million.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1878313/000119312524066954/0001193125-24-066954-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.